Virbac (CHIX:VIRPP) EBIT: €226 Mil (TTM As of Dec. 2025)


CHIX:VIRPP Virbac SA CHIX:VIRPP
95 GF Score
Price €354.25
GF Value €384.87
! 2 Warning Signs
View Full Analysis

What is Virbac EBIT?

Virbac CHIX:VIRPP 95 EBIT is €226 Mil as of Dec. 2025. GuruFocus rates CHIX:VIRPP with a GF Score™ of 95/100 and a GF Value™ of €384.87. The stock has 2 warning signs investors should review.

Virbac's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €97 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €226 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Virbac's annualized ROC % for the quarter that ended in Dec. 2025 was 10.33%. Virbac's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 27.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Virbac's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 7.45%.

Virbac  (CHIX:VIRPp) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Virbac's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=195.428 * ( 1 - 27.22% )/( (1357.161 + 1395.356)/ 2 )
=142.2324984/1376.2585
=10.33 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1815.427 - 329.595 - ( 128.671 - max(0, 430.54 - 842.185+128.671))
=1357.161

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1914.167 - 396.311 - ( 122.5 - max(0, 516.31 - 791.89+122.5))
=1395.356

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Virbac's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=194.896/( ( (434.351 + max(322.579, 0)) + (461.75 + max(209.868, 0)) )/ 2 )
=194.896/( ( 756.93 + 671.618 )/ 2 )
=194.896/714.274
=27.29 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(223.419 + 395.504 + 37.52) - (329.595 + 0 + 4.269)
=322.579

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(201.154 + 378.791 + 31.579) - (396.311 + 0 + 5.345)
=209.868

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Virbac's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=226.339/3036.827
=7.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac EBIT Related Terms

Virbac EBIT Historical Data

* Premium members only.

The historical data trend for Virbac's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac EBIT Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 165.09 180.13 183.04 218.91 226.34

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.48 147.81 71.10 128.89 97.45

CHIX:VIRPP vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Virbac's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virbac EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Virbac's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Virbac's EV-to-EBIT falls into.


CHIX:VIRPP
95GF Score
Virbac SA CHIX:VIRPP
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €226 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €226 Mil mean?
Virbac (CHIX:VIRPP) has a EBIT of €226 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Virbac.
Is Virbac's EBIT too high?
Virbac's current EBIT is €226 Mil. Overall, Virbac has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Virbac's EBIT compare to LLY and JNJ?
Virbac's EBIT of €226 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Virbac. Virbac's current EBIT is €226 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Virbac (CHIX:VIRPP) has a current EBIT of €226 Mil. The stock's GF Value™ is €384.87, compared to a current price of €354.25 — trading 8% below its estimated fair value. The current EBIT is €226 Mil. Virbac's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current EBIT is €226 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (CHIX:VIRPP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €354.25 is trading 8% below its estimated GF Value™ of €384.87.

Key valuation signals for CHIX:VIRPP:

  • EBIT: €226 Mil
  • GF Value™: €384.87 vs. price of €354.25 (8% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score

Get the complete analysis for CHIX:VIRPP

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€354.25
Price
€384.87
GF Value